ArticleHeart rhythm O22025
Management and outcome of different types of ventricular tachycardia associated with hypokalemia.
Article in Heart rhythm O2, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypokalemia is a potentially reversible cause of ventricular tachyarrhythmias (VTAs) such as polymorphic ventricular tachycardia/ventricular fibrillation (PMVT/VF) and sustained monomorphic ventricular tachycardia (SMVT). Despite its established role in arrhythmogenesis, the clinical implications of hypokalemia in patients with distinct VTA subtypes remain poorly understood. Objective: The aims of this study were to study the clinical characteristics, management, and outcome of patients with hypokalemia-associated VTAs and to investigate the prognosis of distinct VTA subtypes after correction of hypokalemia with or without additional VT-targeted therapies (VTTTs), such as catheter ablation or antiarrhythmic drugs. Methods: Consecutive patients admitted with hypokalemia-associated VTAs were analyzed after hypokalemia correction. Patients were categorized by VTA subtype and followed for VT recurrence, 24-month VT-free survival, and all-cause mortality. Those with other reversible causes of VTAs were excluded. Results: Sixty-five patients (mean age 69 ± 12 years; 20% (n = 13) women; mean left ventricular ejection fraction 32% ± 13%; 54% (n = 35) with New York Heart Association class III/IV; 8% (n = 5) with a left ventricular assist device) were studied; 68% (n = 44) presented with SMVT. Patients with SMVT were younger (65 ± 11 years vs 77 ± 10 years; Conclusion: Hypokalemia-associated VTAs are associated with advanced heart failure and linked to poor outcomes, especially in patients with SMVT. Although potassium correction may be sufficient for patients with hypokalemia-associated PMVT/VF, those with SMVT require additional VTTTs to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.